Compare PPCB & YFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPCB | YFOR |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | Australia | Singapore |
| Employees | N/A | N/A |
| Industry | | Professional Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 18.4M |
| IPO Year | 2011 | 2023 |
| Metric | PPCB | YFOR |
|---|---|---|
| Price | $1.65 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 125.5K | ★ 2.7M |
| Earning Date | 11-24-2026 | 09-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.83 |
| Revenue Next Year | N/A | $31.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.05 |
| 52 Week High | $6.79 | $2.05 |
| Indicator | PPCB | YFOR |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 19.22 |
| Support Level | $1.23 | N/A |
| Resistance Level | $1.98 | $2.05 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 58.65 | 1.11 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.